BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up? Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

Dubai: The Emirates Medicines Establishment has launched its Contact Center at 80033784 (800Edrug), which will serve as a ...

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety ...

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​Enrollment for registrational Phase ...

Dr. Shukla continued, “We are encouraged by the potential of efzofitimod to improve the lives of those living with sarcoidosis, and we are incredibly grateful to the patients, investigators, patient ...

Nurix Therapeutics, Inc. ( NASDAQ: NRIX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT ...

Inflammasome Therapeutics ( is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ophthalmic and neurological conditions. Today, the company ...